CY1112440T1 - Απογλυκοζυλιωμενη και αποσιαλιδωμενη μακρα πεντραξινη ρτχ3 - Google Patents
Απογλυκοζυλιωμενη και αποσιαλιδωμενη μακρα πεντραξινη ρτχ3Info
- Publication number
- CY1112440T1 CY1112440T1 CY20111100788T CY111100788T CY1112440T1 CY 1112440 T1 CY1112440 T1 CY 1112440T1 CY 20111100788 T CY20111100788 T CY 20111100788T CY 111100788 T CY111100788 T CY 111100788T CY 1112440 T1 CY1112440 T1 CY 1112440T1
- Authority
- CY
- Cyprus
- Prior art keywords
- aplygylzyzylened
- disinfected
- long pentraxin
- pentraxin ptx3
- diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Reproductive Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Cell Biology (AREA)
- Cardiology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
Abstract
Αποκαλύπτονται απογλυκοζυλιωμένη μακρά πεντραξίνη ΡΤΧ3 και αποσιαλιδωμένη μακρά πεντραξίνη ΡΤΧ3, καθώς και μέθοδοι για την παρασκευή τους, φαρμακευτικές συνθέσεις οι οποίες τις περιέχουν και η χρήση τους για την παρασκευή φαρμάκου για τη θεραπεία νόσων στις οποίες ενδείκνυται η χρήση της μακράς πεντραξίνης ΡΤΧ3, ιδίως λοιμωδών και φλεγμονωδών νόσων και παθήσεων της γυναικείας γονιμότητας. Αυτές οι πρωτεΐνες διαθέτουν θεραπευτική δραστικότητα ανώτερη εκείνης της γλυκοζυλιωμένης πεντραξίνης.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT000489A ITRM20040489A1 (it) | 2004-10-08 | 2004-10-08 | Pentraxina lunga ptx3 deglicosilata o desialidata. |
EP05789623A EP1797120B1 (en) | 2004-10-08 | 2005-09-28 | Deglycosylated and desialidated long pentraxin ptx3 |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1112440T1 true CY1112440T1 (el) | 2015-12-09 |
Family
ID=35708940
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20111100788T CY1112440T1 (el) | 2004-10-08 | 2011-08-17 | Απογλυκοζυλιωμενη και αποσιαλιδωμενη μακρα πεντραξινη ρτχ3 |
Country Status (24)
Country | Link |
---|---|
US (2) | US7683032B2 (el) |
EP (1) | EP1797120B1 (el) |
JP (1) | JP5014999B2 (el) |
KR (1) | KR101426783B1 (el) |
CN (1) | CN101035805B (el) |
AR (1) | AR051053A1 (el) |
AT (1) | ATE509950T1 (el) |
AU (1) | AU2005291280B2 (el) |
BR (1) | BRPI0516554A (el) |
CA (1) | CA2580426C (el) |
CY (1) | CY1112440T1 (el) |
DK (1) | DK1797120T3 (el) |
ES (1) | ES2366370T3 (el) |
HK (1) | HK1110870A1 (el) |
HR (1) | HRP20110595T1 (el) |
IT (1) | ITRM20040489A1 (el) |
ME (1) | ME01947B (el) |
MX (1) | MX2007003904A (el) |
PL (1) | PL1797120T3 (el) |
PT (1) | PT1797120E (el) |
RS (1) | RS51900B (el) |
SI (1) | SI1797120T1 (el) |
TW (1) | TWI380995B (el) |
WO (1) | WO2006037744A1 (el) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1298487B1 (it) * | 1997-12-19 | 2000-01-10 | Sigma Tau Ind Farmaceuti | Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale, |
ITRM20040223A1 (it) * | 2004-05-07 | 2004-08-07 | Sigma Tau Ind Farmaceuti | Medicamento per il trattamento delle infezioni fungine, in particolare dell'aspergillosi. |
EP1832295A1 (en) * | 2006-03-10 | 2007-09-12 | Tecnogen S.P.A. | Use of PTX3 for the treatment of viral diseases |
WO2009095403A1 (en) * | 2008-01-29 | 2009-08-06 | Tecnogen S.P.A. | Expression system and uses thereof for the production of human long pentraxin 3 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1298487B1 (it) * | 1997-12-19 | 2000-01-10 | Sigma Tau Ind Farmaceuti | Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale, |
IT1317927B1 (it) * | 2000-11-03 | 2003-07-15 | Sigma Tau Ind Farmaceuti | Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patologie autoimmuni. |
IT1317930B1 (it) | 2000-11-08 | 2003-07-15 | Sigma Tau Ind Farmaceuti | Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patalogie associate ad una alterata attivazione |
WO2003011902A1 (en) | 2001-07-27 | 2003-02-13 | Kenton S.R.L. | Identification of specific tumour antigens by selection of cdna libraries with sera |
KR100890999B1 (ko) * | 2001-08-03 | 2009-03-31 | 시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이. | 여성 불임증 치료용 긴 펜트락신 ptx3의 용도 |
ITRM20020109A1 (it) * | 2002-02-28 | 2003-08-28 | Sigma Tau Ind Farmaceuti | Derivati funzionali della pentraxina lunga ptx3 per preparare un vaccino autologo per la cura dei tumori. |
ITRM20020191A1 (it) | 2002-04-08 | 2003-10-08 | Sigma Tau Ind Farmaceuti | Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patologie tumorali associate ad una alterata att |
ITRM20040223A1 (it) * | 2004-05-07 | 2004-08-07 | Sigma Tau Ind Farmaceuti | Medicamento per il trattamento delle infezioni fungine, in particolare dell'aspergillosi. |
-
2004
- 2004-10-08 IT IT000489A patent/ITRM20040489A1/it unknown
-
2005
- 2005-09-26 TW TW094133381A patent/TWI380995B/zh not_active IP Right Cessation
- 2005-09-28 ES ES05789623T patent/ES2366370T3/es active Active
- 2005-09-28 JP JP2007535139A patent/JP5014999B2/ja not_active Expired - Fee Related
- 2005-09-28 CA CA2580426A patent/CA2580426C/en not_active Expired - Fee Related
- 2005-09-28 SI SI200531343T patent/SI1797120T1/sl unknown
- 2005-09-28 US US11/575,346 patent/US7683032B2/en not_active Expired - Fee Related
- 2005-09-28 ME MEP-2011-356A patent/ME01947B/me unknown
- 2005-09-28 EP EP05789623A patent/EP1797120B1/en active Active
- 2005-09-28 DK DK05789623.5T patent/DK1797120T3/da active
- 2005-09-28 WO PCT/EP2005/054860 patent/WO2006037744A1/en active Application Filing
- 2005-09-28 KR KR1020077009215A patent/KR101426783B1/ko not_active IP Right Cessation
- 2005-09-28 MX MX2007003904A patent/MX2007003904A/es active IP Right Grant
- 2005-09-28 AT AT05789623T patent/ATE509950T1/de active
- 2005-09-28 PT PT05789623T patent/PT1797120E/pt unknown
- 2005-09-28 CN CN2005800342474A patent/CN101035805B/zh not_active Expired - Fee Related
- 2005-09-28 PL PL05789623T patent/PL1797120T3/pl unknown
- 2005-09-28 AU AU2005291280A patent/AU2005291280B2/en not_active Ceased
- 2005-09-28 BR BRPI0516554-7A patent/BRPI0516554A/pt not_active IP Right Cessation
- 2005-09-28 RS RS20110356A patent/RS51900B/en unknown
- 2005-10-05 AR ARP050104203A patent/AR051053A1/es not_active Application Discontinuation
-
2008
- 2008-02-06 HK HK08101469.2A patent/HK1110870A1/xx not_active IP Right Cessation
-
2010
- 2010-02-23 US US12/710,559 patent/US7833981B2/en not_active Expired - Fee Related
-
2011
- 2011-08-11 HR HR20110595T patent/HRP20110595T1/hr unknown
- 2011-08-17 CY CY20111100788T patent/CY1112440T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
US7833981B2 (en) | 2010-11-16 |
AU2005291280A1 (en) | 2006-04-13 |
DK1797120T3 (da) | 2011-09-05 |
HRP20110595T1 (hr) | 2011-09-30 |
ITRM20040489A1 (it) | 2005-01-08 |
RS51900B (en) | 2012-02-29 |
EP1797120A1 (en) | 2007-06-20 |
CA2580426C (en) | 2015-01-13 |
JP2008515846A (ja) | 2008-05-15 |
CA2580426A1 (en) | 2006-04-13 |
KR101426783B1 (ko) | 2014-08-05 |
TW200628488A (en) | 2006-08-16 |
SI1797120T1 (sl) | 2011-12-30 |
PT1797120E (pt) | 2011-08-23 |
AR051053A1 (es) | 2006-12-13 |
MX2007003904A (es) | 2007-06-07 |
CN101035805B (zh) | 2011-04-06 |
ME01947B (me) | 2012-02-29 |
ES2366370T3 (es) | 2011-10-19 |
WO2006037744A1 (en) | 2006-04-13 |
HK1110870A1 (en) | 2008-07-25 |
US20100209442A1 (en) | 2010-08-19 |
US7683032B2 (en) | 2010-03-23 |
KR20070083769A (ko) | 2007-08-24 |
JP5014999B2 (ja) | 2012-08-29 |
AU2005291280B2 (en) | 2011-10-20 |
US20070249021A1 (en) | 2007-10-25 |
EP1797120B1 (en) | 2011-05-18 |
BRPI0516554A (pt) | 2008-09-09 |
CN101035805A (zh) | 2007-09-12 |
PL1797120T3 (pl) | 2011-12-30 |
TWI380995B (zh) | 2013-01-01 |
ATE509950T1 (de) | 2011-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20064186L (no) | Substituerte pyrazolin sammensetninger for a redusere triglycerider i blod | |
NO20053077L (no) | Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer. | |
NO20060185L (no) | Anvendelse av isomalt (blanding av 1,6 GPS og 1,1 GPM) som prebiotikum blant annet for fremstilling av et legemiddel for behandling av tarmsykdommer | |
CY1118849T1 (el) | Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης | |
HUP0401534A2 (hu) | Módosított humán IX. faktor | |
BRPI0912411B8 (pt) | uso de uma muteína de interleucina humana-2 (muteína de hil-2) e composição farmacêutica para o tratamento e/ou profilaxia de uma doença autoimune | |
CY1115082T1 (el) | Υποκατεστημενα παραγωγα 1,3-διφαινυλπροπανιου, παρασκευες και χρησεις αυτων | |
ATE466085T1 (de) | Protease-resistente modifizierte interferon alpha polypeptide | |
NO20064041L (no) | Substituerte pyrazolin sammensetninger, deres fremstilling og anvendelse som medikamenter | |
CY1112115T1 (el) | Παραγωγα φαινοξυοξικου οξεος χρησιμα για τη θεραπευτικη αντιμετωπιση ασθενειων του αναπνευστικου | |
NO20045521L (no) | Diarylureaderivater anvendelige for behandling av proteinkinaseavhengige sykdommer | |
CY1108932T1 (el) | Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων | |
IL164373A (en) | Benzamide derivatives, pharmaceutical compositions containing them, process for their preparation and use thereof in the manufacture of medicaments and as medicaments in the treatment of diseases associated with cancer | |
ATE516037T1 (de) | Topische formulierung von ivermectin zur behandlung von dermatologischen erkrankungen | |
CY1108992T1 (el) | Η χρηση του υαλουρονικου οξεος για την παρασκευη συνθεσεων για τη θεραπευτικη αντιμετωπιση υποτροπιαζουσων αφθων της στοματικης κοιλοτητας | |
ATE460940T1 (de) | Eisen(iii) komplex-verbindungen zur oralen behandlung von eisenmangel bei patienten mit chronischen entzündlichen darmerkrankungen | |
DE60219314D1 (de) | Halogenhaltige zusammensetzung, verfahren zu deren herstellung und deren verwendung | |
IL209879A0 (en) | Substituted pteridines ,pharmaceutical compositions containing them and their use in the manufacture of medicaments for treating inflammatory diseases | |
ATE516366T1 (de) | Regulierte aptamer-therapeutika | |
CY1112440T1 (el) | Απογλυκοζυλιωμενη και αποσιαλιδωμενη μακρα πεντραξινη ρτχ3 | |
NO20076405L (no) | Anvendelse av 24-nor-UDCA | |
CY1107231T1 (el) | Υποκατεστημενα παραγωγα 4-αμινοκυκλοεξανολης | |
DE502004008793D1 (el) | ||
ATE413187T1 (de) | Pharmazeutische zusammensetzungen mit interferon- tau | |
BRPI0506929A (pt) | composições de gel macio dermatológicas |